MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study
NCT02334371 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2016-03-16
Summary
The importance of selecting patients with ovarian cancer who will benefit from either primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery has been acknowledged worldwide but the optimal diagnostic modality to serve in this matter remains to be discovered. We believe that combined magnetic resonance imaging and positron emission tomography (MR-PET) can be of great clinical value in preoperative staging of patients with ovarian cancer.
Conditions
- Ovarian Neoplasms
Interventions
- RADIATION
-
MR-PET
The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
Sponsors & Collaborators
-
Maastricht University Medical Center
lead OTHER
Principal Investigators
-
Toon Van Gorp · Maastricht University Medical Centre
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-30
- Primary Completion
- 2016-03-31
- Completion
- 2016-03-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT02243059 ·Status: WITHDRAWN ·Phase: PHASE4
-
Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
NCT01826227 ·Status: COMPLETED ·Phase: NA
-
Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study
NCT00946140 ·Status: COMPLETED
-
Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging
NCT02792959 ·Status: COMPLETED ·Phase: NA
-
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer
NCT04999917 ·Status: COMPLETED ·Phase: NA
-
Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics
NCT02144311 ·Status: COMPLETED ·Phase: NA
-
Prediction of Clinical Response and Outcome in Uterine Cervix Cancer
NCT01764217 ·Status: COMPLETED
-
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
NCT00959582 ·Status: COMPLETED ·Phase: PHASE1
-
Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis
NCT01242436 ·Status: COMPLETED ·Phase: NA
-
PET/MRI in Endometrial Cancer
NCT05390021 ·Status: WITHDRAWN ·Phase: NA
-
68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings
NCT04504110 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
NCT06232122 ·Status: RECRUITING ·Phase: NA
-
Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data
NCT06533709 ·Status: RECRUITING
-
Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study
NCT00686465 ·Status: COMPLETED ·Phase: NA
-
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
NCT00612326 ·Status: COMPLETED
-
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
NCT02765698 ·Status: TERMINATED
-
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
NCT01717391 ·Status: COMPLETED ·Phase: PHASE2
-
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
NCT01439490 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
NCT05856409 ·Status: RECRUITING
-
FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment
NCT03489473 ·Status: UNKNOWN
-
Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases
NCT02316431 ·Status: COMPLETED
-
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
NCT06835426 ·Status: RECRUITING ·Phase: NA
-
Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
NCT06061874 ·Status: RECRUITING ·Phase: NA
-
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients
NCT01834469 ·Status: COMPLETED ·Phase: PHASE1/PHASE2